Drug Type CAR-T |
Synonyms CLDN18.2/TGF-β bispecific CAR-T cells(ImmPAC) |
Target |
Action inhibitors, stimulants |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), TGF-β stimulants(Transforming growth factor beta stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stomach Cancer | Preclinical | United States | 08 May 2024 | |
CLDN18.2 positive Stomach Cancer | Discovery | United States | 07 May 2024 |